CDK4 and cancer: First, by examining a cohort of patients with detailed treatment histories, we established that APOBEC3 mutagenesis is associated with shorter outcomes on targeted therapies, including antiestrogen monotherapy and antiestrogen plus CDK4/6i combinations among HR+ cancers.